{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T04:17:49Z","timestamp":1743567469157,"version":"3.40.3"},"reference-count":35,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Cardiol Young"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S1047951124025903_as1\"><jats:title>Introduction:<\/jats:title><jats:p>Acute rheumatic fever commonly causes carditis in children. It is critical to have biomarkers for diagnostic and prognostic purposes. We aimed to investigate the expressions of miR-101, miR-1183, and miR-1299 in children with acute rheumatic fever and rheumatic heart disease and determine their potential as diagnostic biomarkers.<\/jats:p><\/jats:sec><jats:sec id=\"S1047951124025903_as2\"><jats:title>Methods:<\/jats:title><jats:p>This cross-sectional study was conducted on 69 paediatric acute rheumatic fever patients and 27 gender and age-matched controls. The clinical findings were noted from medical records, echocardiography was repeated, and plasma miR-101, miR-1183, and miR-1299 expressions were studied using RT-PCR.<\/jats:p><\/jats:sec><jats:sec id=\"S1047951124025903_as3\"><jats:title>Results:<\/jats:title><jats:p>Out of 54 patients with carditis, 36 developed rheumatic heart disease with significant left-sided heart involvement. No significant demographic difference was present between rheumatic heart disease patients and controls (<jats:italic>p<\/jats:italic> &gt; 0.05). miR-101 and miR-1183 expressions significantly reduced by 4.5-fold in acute rheumatic fever patients compared to controls (<jats:italic>p<\/jats:italic> : 0.029 and <jats:italic>p<\/jats:italic> : 0.024, respectively). Family history was found to be significantly associated with 9-fold reduced miR-1183 expression in acute rheumatic fever patients (<jats:italic>p<\/jats:italic> : 0.005). The expression of miR-1183 in acute rheumatic fever children with carditis in general and severe carditis was significantly reduced 4.5- and 9-fold, respectively (<jats:italic>p<\/jats:italic> : 0.024 and <jats:italic>p<\/jats:italic> : 0.007, respectively). In acute rheumatic fever cases with moderate-severe carditis and patients who did not develop rheumatic heart disease, miR-1183 expression significantly reduced 8.3-fold and 9-fold, respectively (<jats:italic>p<\/jats:italic> : 0.015 and <jats:italic>p<\/jats:italic> : 0.019, respectively). The ROC analysis revealed that miR-101 and miR-1183 were statistically significant for acute rheumatic fever diagnosis (AUC: 0.64 for both miRNAs).<\/jats:p><\/jats:sec><jats:sec id=\"S1047951124025903_as4\"><jats:title>Conclusions:<\/jats:title><jats:p>Significantly lower plasma expressions of miR-101 and miR-1183 in acute rheumatic fever patients, especially in cases with moderate-severe carditis, might indicate the potential use of these miRNAs as diagnostic biomarkers.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1047951124025903","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T08:22:36Z","timestamp":1738570956000},"page":"458-465","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":0,"title":["The roles of miR-101, miR-1183 and miR-1299 in acute rheumatic fever and rheumatic heart disease"],"prefix":"10.1017","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9967-4707","authenticated-orcid":false,"given":"Ece","family":"Korkmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-9791","authenticated-orcid":false,"given":"Dolunay","family":"G\u00fcrses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6khan","family":"\u00c7etin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hande","family":"Senol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"S1047951124025903_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2020.01.002"},{"key":"S1047951124025903_ref35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21020561"},{"key":"S1047951124025903_ref31","doi-asserted-by":"publisher","DOI":"10.1266\/ggs.17-00043"},{"key":"S1047951124025903_ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-4069-2"},{"key":"S1047951124025903_ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000205"},{"key":"S1047951124025903_ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-019-03128-7"},{"key":"S1047951124025903_ref8","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2017.4652"},{"key":"S1047951124025903_ref23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17071120"},{"key":"S1047951124025903_ref13","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6449"},{"key":"S1047951124025903_ref21","doi-asserted-by":"publisher","DOI":"10.3390\/biom10010035"},{"key":"S1047951124025903_ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-018-0788-2"},{"key":"S1047951124025903_ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000369689"},{"key":"S1047951124025903_ref24","doi-asserted-by":"publisher","DOI":"10.1186\/ar4114"},{"key":"S1047951124025903_ref25","first-page":"1","article-title":"MicroRNA as a therapeutic target in cardiac remodeling","volume":"2017","author":"Chen","year":"2017","journal-title":"Biomed Res Int"},{"key":"S1047951124025903_ref32","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S250396"},{"key":"S1047951124025903_ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2012.7"},{"key":"S1047951124025903_ref34","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00866.2008"},{"key":"S1047951124025903_ref33","doi-asserted-by":"publisher","DOI":"10.1038\/srep24580"},{"key":"S1047951124025903_ref27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221900"},{"key":"S1047951124025903_ref26","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00006.2010"},{"key":"S1047951124025903_ref17","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.12659\/MSM.893540","article-title":"Down-regulation of miR-101 contributes to rheumatic heart disease through up-regulating TLR2","volume":"21","author":"Dong","year":"2015","journal-title":"Med Sci Monit"},{"key":"S1047951124025903_ref19","unstructured":"19. Heart Foundation New Zealand. Algorithm 3: guide for the duration of secondary prophylaxis in acute rheumatic fever (ARF) 2020. https:\/\/assets.heartfoundation.org.nz\/documents\/shop\/heart-healthcare\/non-stock-resources\/secondary-prophylaxis-rheumatic-fever-algorithm.pdf."},{"key":"S1047951124025903_ref10","first-page":"60","article-title":"MicroRNA and cardiovascular diseases","volume":"37","author":"\u00c7akmak","year":"2020","journal-title":"Balkan Med J"},{"key":"S1047951124025903_ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03009"},{"key":"S1047951124025903_ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-018-4876-6"},{"key":"S1047951124025903_ref22","doi-asserted-by":"publisher","DOI":"10.4236\/wjcd.2017.710032"},{"key":"S1047951124025903_ref5","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-309188"},{"key":"S1047951124025903_ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603693"},{"key":"S1047951124025903_ref6","doi-asserted-by":"publisher","DOI":"10.1017\/S1047951115002413"},{"key":"S1047951124025903_ref18","first-page":"1","article-title":"Detection of differentially expressed MicroRNAs in rheumatic heart disease: miR-1183 and miR-1299 as potential diagnostic biomarkers","volume":"2015","author":"Li","year":"2015","journal-title":"Biomed Res Int"},{"key":"S1047951124025903_ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1411-0"},{"key":"S1047951124025903_ref14","first-page":"429","article-title":"Inhibition of miR-155-5p attenuates the valvular damage induced by rheumatic heart disease","volume":"45","author":"Chen","year":"2020","journal-title":"Int J Mol Med"},{"key":"S1047951124025903_ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jocs.14636"},{"key":"S1047951124025903_ref12","doi-asserted-by":"publisher","DOI":"10.1017\/S2040174418000387"},{"key":"S1047951124025903_ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-020-03743-5"}],"container-title":["Cardiology in the Young"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1047951124025903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T12:05:21Z","timestamp":1743509121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1047951124025903\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1047951124025903"],"URL":"https:\/\/doi.org\/10.1017\/s1047951124025903","relation":{},"ISSN":["1047-9511","1467-1107"],"issn-type":[{"type":"print","value":"1047-9511"},{"type":"electronic","value":"1467-1107"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"\u00a9 The Author(s), 2025. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}